Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at BMO Capital; Makes Case for $165 Upside Scenario
September 21, 2017 3:40 PM EDTBMO Capital analyst Do Kim raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $134.00 (from $99.00) while maintaining an Outperform rating following strong APOLLO data.
"We believe an early restart of Fitusiran trials and positive Givosiran interim data (mid-2018) would enable shares to approach our $165 upside scenario," the analyst said.
... MoreAlnylam Pharmaceuticals (ALNY) PT Raised to $101 at Morgan Stanley
September 21, 2017 8:37 AM EDTMorgan Stanley raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $101.00 (from $50.00) while maintaining a Equalweight rating.
... MoreAlnylam Pharmaceuticals (ALNY) PT Raised to $135 at Bernstein
September 21, 2017 7:23 AM EDTBernstein raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $135.00 (from $94.00) while maintaining a Outperform rating.
Analyst Vincent Chen echos his previous LT optimism in the company and expects siRNA to evolve into a new class of drugs which... More
UPDATE: Alnylam Pharmaceuticals (ALNY) PT Raised to $146 at Ladenburg Thalmann
September 21, 2017 7:04 AM EDT(Updated - September 21, 2017 7:08 AM EDT)
(updated to add analyst comment)
Ladenburg Thalmann analyst Christopher James raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $146.00 (from $90.00) while maintaining a Buy rating.
The analyst is positive on the results from... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit Suisse
September 21, 2017 6:26 AM EDTCredit Suisse analyst Alethia Young raised her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $123.00 (from $96.00) while maintaining an Outperform rating following positive APOLLO trial data.
Young thinks porphyria data in mid-2018 and patisiran's expansion into the cardiac subtype can continue... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities
September 20, 2017 2:14 PM EDTJMP Securities analyst Michael King raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $101.00) while maintaining a Market Outperform rating after the company announced positive top-line results for the Phase III APOLLO trial.
"We believe patisirans success in APOLLO... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at Stifel
September 20, 2017 1:41 PM EDTStifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $83.00 (from $56.00) while maintaining a Hold rating.
... MoreAlnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'
September 20, 2017 12:36 PM EDTCowen raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $117.00 (from $93.00) while maintaining a Outperform rating after the company released positive top-line data from the pivotal Ph3 APOLLO trial of patisiran in FAP with strong statistical significance.
Analyst Ritu Baral... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper Jaffray
September 20, 2017 11:39 AM EDT(updated to expand analyst comment)
Piper Jaffray analyst Edward Tenthoff raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $110.00) while maintaining a Overweight rating following positive APOLLO Phase 3 data on patisiran.
The analyst anticipates cardiac subgroup data with the... More
Royalty Stream to Arbutus Biopharma (ABUS) from Alnylam (ALNY) 'Could be Significant' - Wedbush
September 20, 2017 10:19 AM EDTWedbush analyst Robert Driscoll weighed in on Arbutus Biopharma (NASDAQ: ABUS) after Alnylam (NASDAQ: ALNY) reported positive data from its Ph 3 study APOLLO of patisiran in patients with hereditary ATTR amyloidosis.
Driscoll notes Patisiran is an RNAi therapeutic... More
Arbutus Biopharma (ABUS) Gains Sharply Following Alnylam Trial Success
September 20, 2017 10:12 AM EDTArbutus Biopharma (NASDAQ: ABUS) gains 10.8% early after Sanofi Genzyme and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints
... MorePre-Open Stock Movers 09/20: (ALNY) (KPTI) (GEMP) Higher; (BBBY) (IONS) (GIS) Lower (more...)
September 20, 2017 9:29 AM EDTToday's Pre-Open Movers
Alnylam Pharma (NASDAQ: ALNY) 31.3% HIGHER; the company and partner Sanofi announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints.
Cesca Therapeutics Inc. (NASDAQ:... More
Alnylam Pharma (ALNY) Gains 22% on Patisiran Phase 3 Trial Success
September 20, 2017 7:53 AM EDTAlnylam Pharma (NASDAQ: ALNY) shares are trading up 22% in pre-open trade after the company and partner Sanofi announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints.
... MoreIonis Pharma (IONS) Sinks on Alnylam (ALNY) Patisiran Success
September 20, 2017 7:36 AM EDTIonis Pharma (NASDAQ: IONS) sinks 12% in pre-open trade after Sanofi Genzyme and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints.
... MoreAlnylam Pharma (ALNY) to Resume Trading at 7:30 AM ET
September 20, 2017 7:06 AM EDTAlnylam Pharma (NASDAQ: ALNY) to Resume Trading at 7:30 AM ET
... MoreSanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
September 20, 2017 7:02 AM EDTSanofi Genzyme and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met... More
Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary Endpoints
September 20, 2017 7:01 AM EDTSanofi Genzyme, the specialty care global business unit of Sanofi (NYSE: SNY), and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met... More
